Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes (original) (raw)
Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998 Jul; 339(4): 229–34 ArticlePubMedCAS Google Scholar
Idris I, Thomson GA, Sharma JC. Diabetes mellitus and stroke. Int J Clin Pract 2006; 60(1): 48–56 ArticlePubMedCAS Google Scholar
Juutilainen A, Lehto S, Rönnemaa T, et al. Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005; 28(12): 2901–7 ArticlePubMed Google Scholar
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec; 106: 3143–421 Google Scholar
Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998 Jan; 21(1): 69–75 ArticlePubMedCAS Google Scholar
Mukamal KJ, Nesto RW, Cohen MC, et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care 2001 Aug; 24(8): 1422–7 ArticlePubMedCAS Google Scholar
Roper NA, Bilous RW, Kelly WF, et al. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal population based study. BMJ 2001 Jun; 322(7299): 1389–93 ArticlePubMedCAS Google Scholar
Dormandy JA, Charbonnel B, Eckland DJ, et al., PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro-Vascular Events): a randomised controlled trial. Lancet 2005 Oct; 366: 1279–89 ArticlePubMedCAS Google Scholar
Betteridge DJ, DeFronzo RA, Chilton RJ. PROactive: time for a critical appraisal. Eur Heart J 2008 Apr; 29(8): 969–83 201 ArticlePubMed Google Scholar
Wilcox R, Kupfer S, Erdmann E, PROactive Study investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J 2008 Apr; 155(4): 712–7 ArticlePubMedCAS Google Scholar
Erdmann E, Dormandy JA, Charbonnel B, et al., PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. Results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49(17): 1772–80 ArticlePubMedCAS Google Scholar
Wilcox R, Bousser MG, Betteridge DJ, et al., PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007 Sep; 38: 865–73 ArticlePubMedCAS Google Scholar
Massi-Benedetti M, Scheen A, Charbonnel B. Pioglitazone delays the need for permanent insulin use: results from PROactive [abstract]. Diabetes 2006; 55: A124 Google Scholar
Charbonnel B, Dormandy J, Erdmann E, et al., PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004 Jul; 27(7): 1647–53 ArticlePubMed Google Scholar
Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract 2007 May; 76(2): 279–89 ArticlePubMedCAS Google Scholar
Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione-use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004 Jan; 27: 256–63 ArticlePubMedCAS Google Scholar
Raskin P, Rendell M, Riddle MC, et al., Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001 Jul; 24: 1226–32 ArticlePubMedCAS Google Scholar
Rosenstock J, Einhorn D, Hershon K, et al., Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002 May; 56: 251–7 PubMedCAS Google Scholar
Tang WHW. Do thiazolidinediones cause heart failure? A critical review. Cleve Clin J Med 2006 Jun; 73(4): 390–7 ArticlePubMed Google Scholar
Scheen A, Charbonnel B. Reduced insulin requirements and improved glycemic control with pioglitazone in insulin-treated patients with type 2 diabetes: results from PROactive [abstract]. Diabetes 2006; 55 Suppl. 2: A134 Google Scholar
Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004 Aug; 27: 1879–84 ArticlePubMed Google Scholar
Masoudi FA, Inzucchi SE. Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol 2007; 99(4A): 113–32B Article Google Scholar
Fang ZY, Schull-Meade R, Downey M, et al. Determinants of subclinical diabetic heart disease. Diabetologia 2005; 48: 394–402 ArticlePubMedCAS Google Scholar
Fang ZY, Schull-Meade R, Leano R, et al. Screening for heart disease in diabetic subjects. Am Heart J 2005; 149: 349–54 ArticlePubMed Google Scholar
Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007 Aug; 38: 2148–53 Article Google Scholar
Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007 Sep; 370(9593): 1129–36 ArticlePubMedCAS Google Scholar
Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 2008; 29: 12–20 ArticlePubMedCAS Google Scholar
Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone versus glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008 Apr 2; 299(13): 1561–73 ArticlePubMedCAS Google Scholar
Erdmann E, Charbonnel B, Wilcox RG, et al., PROactive investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007 Nov; 30: 2773–8 ArticlePubMedCAS Google Scholar
Rydén L, Thráinsdóttir I, Swedberg K. Adjudication of serious heart failure in patients from PROactive [letter]. Lancet 2007; 368: 189–90 Article Google Scholar
Giles T, Miller A, Elkayam U, et al. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Cardiac Failure 2008 Aug; 14(6): 445–52 ArticleCAS Google Scholar
Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111: 583–90 ArticlePubMedCAS Google Scholar
Aguilar D, Bozkurt B, Pritchett A, et al. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol 2007 Jul 3; 50(1): 32–6 ArticlePubMedCAS Google Scholar
Schwartz AV, Sellmeyer DE. Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance? Diabetes Care 2007 Jun; 30: 1670–1 ArticlePubMedCAS Google Scholar
Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008 May; 31(5): 845–51 ArticlePubMedCAS Google Scholar
Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008 Apr 28; 168(8): 820–5 ArticlePubMedCAS Google Scholar
Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008 Feb; 19(2): 129–37 ArticlePubMedCAS Google Scholar
Short R. Fracture risk is a class effect of glitazones. BMJ 2007 Mar; 334(7593): 551 ArticlePubMed Google Scholar
Heine R, Schindhelm R, Diamant M. Long-term pioglitazone treatment improves markers of liver function: results from PROactive [abstract]. Diabetes 2006; 55 Suppl. 1: A115 Google Scholar
Belcher G, Schernthaner G. Changes in liver tests during 1-year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabet Med 2005 Aug; 22: 973–9 ArticlePubMedCAS Google Scholar
Belcher G, Lambert C, Edwards G, et al. Safety and tolerability of pioglitazone, metformin, and gliclazide in the 202 treatment of type 2 diabetes. Diabetes Res Clin Pract 2005 Oct; 70: 53–62 ArticlePubMedCAS Google Scholar
Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006 Nov; 355: 2297–307 ArticlePubMedCAS Google Scholar
Schindhelm RK, Diamant M, Dekker JM, et al. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006 Nov–Dec; 22: 437–43 ArticlePubMedCAS Google Scholar
Ono M, Ikegami H, Fujisawa T, et al. Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones. Metabolism 2005 Apr; 54(4): 529–32 ArticlePubMedCAS Google Scholar
Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004 Jan; 39: 188–96 ArticlePubMedCAS Google Scholar
Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002 Jun; 87(6): 2784–91 ArticlePubMedCAS Google Scholar
Bajaj M, Suraamornkul S, Pratipanawatr T, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003 Jun; 52(6): 1364–70 ArticlePubMedCAS Google Scholar
Rajagopalan R, Iyer S, Perez A. Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. Diabetes Obes Metab 2005 Mar; 7: 161–9 ArticlePubMedCAS Google Scholar
Takeda Pharmaceutical Company Limited. Actos (pioglitazone hydrochloride) US package insert. Osaka: Takeda, 2004 Aug Google Scholar
Nakashiro K, Hayashi Y, Kita A, et al. Role of peroxisome proliferator-activated receptor and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol 2001 Aug; 159(2): 591–7 ArticlePubMedCAS Google Scholar
Charbonnel B, Birkeland K, Scheen A. Pioglitazone add-on to either metformin or sulfonylurea: glycaemic results from PROactive [abstract]. Diabet Med 2006; 23: 298 Google Scholar
Charbonnel B, Scheen A. Pioglitazone in triple oral therapy: long-term glycemic results from PROactive [abstract]. Diabetes 2006; 55 Suppl. 2: A106 Google Scholar
Basu A, Jensen MD, McCann F, et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006 Mar; 29: 510–4 ArticlePubMedCAS Google Scholar
Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 2003 Dec; 115: 111S–5S ArticlePubMedCAS Google Scholar
Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type 2 diabetes mellitus. Diabetologia 1999 Apr; 42: 406–12 ArticlePubMedCAS Google Scholar
Derosa G, Cicero AF, Dangelo A, et al. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res 2005a Nov; 28(11): 917–24 ArticleCAS Google Scholar
Derosa G, Cicero AF, Gaddi A, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005 Jul; 69(1): 5–13 ArticlePubMedCAS Google Scholar
Goldberg RB, Kendall DM, Deeg MA, et al., GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005 Jul; 28(7): 1547–54 ArticlePubMedCAS Google Scholar
Marx N, Wohrle J, Nusser T, et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005 Nov; 112(18): 2792–8 ArticlePubMedCAS Google Scholar
Miyazaki Y, Mahankali A, Wajcberg E, et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004 Sep; 89(9): 4312–9 ArticlePubMedCAS Google Scholar
Perez A, Khan M, Johnson T, et al. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diab Vasc Dis Res 2004 May; 1(1): 44–50 ArticlePubMed Google Scholar
Pfutzner A, Marx N, Lubben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45(12): 1925–31 ArticlePubMed Google Scholar
Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003 Sep; 26(9): 2493–9 ArticlePubMedCAS Google Scholar
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–71 ArticlePubMedCAS Google Scholar
Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007 Sep; 298: 1189–95 ArticlePubMedCAS Google Scholar
Karter AJ, Ahmed AT, Liu J, et al. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005 Aug; 22(8): 986–93 ArticlePubMedCAS Google Scholar
Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007 Sep; 298: 1180–8 ArticlePubMedCAS Google Scholar
Gerrits CM, Bhattacharya M, Manthena S, et al. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007 Oct; 16(10): 1065–71 ArticlePubMed Google Scholar
Lipscombe LL, Gomes T, Lévesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007 Dec 12; 298(22): 2634–43 ArticlePubMedCAS Google Scholar
Spanheimer R, Perez A, Kupfer S, et al. Effects of pioglitazone versus glyburide on markers of liver safety: results from a 3-year, randomized, double-blind trial [abstract]. Diabetes 2006; 55 Suppl. 1: A75 Google Scholar